Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 352

1.

PD-1 Pandemonium at the American Association for Cancer Research Annual Meeting.

Bates SE.

Oncologist. 2019 May;24(5):571-573. doi: 10.1634/theoncologist.2019-0281. No abstract available.

PMID:
31088980
2.

Publish or Perish v2.

Bates SE.

Oncologist. 2019 May 7. pii: theoncologist.2019-0319. doi: 10.1634/theoncologist.2019-0319. [Epub ahead of print] No abstract available.

PMID:
31064889
3.

Delayed cord clamping with stabilisation at all preterm births - feasibility and efficacy of a low cost technique.

Bates SE, Isaac TCW, Marion RL, Norman V, Gumley JS, Sullivan CD.

Eur J Obstet Gynecol Reprod Biol. 2019 May;236:109-115. doi: 10.1016/j.ejogrb.2019.03.012. Epub 2019 Mar 15.

PMID:
30903883
4.

Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T.

Semin Oncol. 2019 Feb;46(1):83-99. doi: 10.1053/j.seminoncol.2019.01.002. Epub 2019 Jan 26. Review.

PMID:
30738604
5.

Neoadjuvant Treatment for Pancreatic Cancer.

Raufi AG, Manji GA, Chabot JA, Bates SE.

Semin Oncol. 2019 Feb;46(1):19-27. doi: 10.1053/j.seminoncol.2018.12.002. Epub 2018 Dec 28. Review.

PMID:
30630600
6.

Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models.

McDonald AJ, Curt KM, Patel RP, Kozlowski H, Sackett DL, Robey RW, Gottesman MM, Bates SE.

Exp Cell Res. 2019 Feb 15;375(2):106-112. doi: 10.1016/j.yexcr.2018.12.012. Epub 2018 Dec 21.

PMID:
30579954
7.

Entinostat finds a path: A new study elucidates effects of the histone deacetylase inhibitor on the immune system.

Surolia I, Bates SE.

Cancer. 2018 Dec 15;124(24):4597-4600. doi: 10.1002/cncr.31766. Epub 2018 Nov 13. No abstract available.

PMID:
30423203
8.

Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research.

Chabner BA, Bates SE.

Oncologist. 2018 Dec;23(12):1391-1393. doi: 10.1634/theoncologist.2018-0662. Epub 2018 Oct 23. No abstract available.

PMID:
30352945
9.

Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K.

Cancer. 2019 Feb 1;125(3):406-415. doi: 10.1002/cncr.31816. Epub 2018 Oct 20.

PMID:
30341983
10.

Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.

J Natl Cancer Inst. 2019 May 1;111(5):490-497. doi: 10.1093/jnci/djy133.

PMID:
30239887
11.

A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.

Peer CJ, Hall OM, Sissung TM, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

Cancer Chemother Pharmacol. 2018 Sep;82(3):565-570. doi: 10.1007/s00280-018-3631-7. Epub 2018 Jun 27.

12.

Revisiting the role of ABC transporters in multidrug-resistant cancer.

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM.

Nat Rev Cancer. 2018 Jul;18(7):452-464. doi: 10.1038/s41568-018-0005-8. Review.

PMID:
29643473
13.

Variation in the management of SSRI-exposed babies across England.

Thomas E, Peacock PJ, Bates SE.

BMJ Paediatr Open. 2017 Aug 11;1(1):e000060. doi: 10.1136/bmjpo-2017-000060. eCollection 2017.

14.

Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.

Zhang GN, Zhang YK, Wang YJ, Gupta P, Ashby CR Jr, Alqahtani S, Deng T, Bates SE, Kaddoumi A, Wurpel JND, Lei YX, Chen ZS.

Cancer Lett. 2018 Jun 28;424:19-29. doi: 10.1016/j.canlet.2018.02.040. Epub 2018 Mar 5.

PMID:
29518481
15.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

PMID:
29420340
16.

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Tang SW, Thomas A, Murai J, Trepel JB, Bates SE, Rajapakse VN, Pommier Y.

Clin Cancer Res. 2018 Apr 15;24(8):1944-1953. doi: 10.1158/1078-0432.CCR-17-0443. Epub 2018 Feb 1.

17.

Mutation Analysis in Cultured Cells of Transgenic Rodents.

Besaratinia A, Zheng A, Bates SE, Tommasi S.

Int J Mol Sci. 2018 Jan 16;19(1). pii: E262. doi: 10.3390/ijms19010262.

18.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y.

J Clin Oncol. 2018 Jun 1;36(16):1594-1602. doi: 10.1200/JCO.2017.76.6915. Epub 2017 Dec 18.

19.

Metabolic symbiosis in cancer and its therapeutic implication.

Lipstein MR, Pal I, Bates SE, Deng C.

Semin Oncol. 2017 Jun;44(3):233-234. doi: 10.1053/j.seminoncol.2017.09.001. Epub 2017 Oct 10. No abstract available.

PMID:
29248135
20.

Limited mutagenicity of electronic cigarettes in mouse or human cells in vitro.

Tommasi S, Bates SE, Behar RZ, Talbot P, Besaratinia A.

Lung Cancer. 2017 Oct;112:41-46. doi: 10.1016/j.lungcan.2017.07.035. Epub 2017 Aug 3.

21.

Current challenges in the management of breast cancer brain metastases.

O'Sullivan CC, Davarpanah NN, Abraham J, Bates SE.

Semin Oncol. 2017 Apr;44(2):85-100. doi: 10.1053/j.seminoncol.2017.06.006. Epub 2017 Jul 8. Review.

PMID:
28923217
22.

Refining Immunotherapy Approvals.

Bates SE.

Clin Cancer Res. 2017 Sep 1;23(17):4948-4949. doi: 10.1158/1078-0432.CCR-17-2025. No abstract available.

23.

Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.

Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S.

Leuk Lymphoma. 2018 Apr;59(4):880-887. doi: 10.1080/10428194.2017.1361022. Epub 2017 Aug 30.

PMID:
28853310
24.

Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels.

Mlejnek P, Kosztyu P, Dolezel P, Bates SE, Ruzickova E.

Chem Biol Interact. 2017 Aug 1;273:171-179. doi: 10.1016/j.cbi.2017.06.012. Epub 2017 Jun 13.

PMID:
28623111
25.

Base Pairs to Populations.

Bates SE.

Clin Cancer Res. 2017 Jun 1;23(11):2610. doi: 10.1158/1078-0432.CCR-16-2631. No abstract available.

26.

Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".

Borazanci E, Dang CV, Robey RW, Bates SE, Chabot JA, Von Hoff DD.

Clin Cancer Res. 2017 Apr 1;23(7):1629-1637. doi: 10.1158/1078-0432.CCR-16-2070. Review.

27.

Pancreatic Cancer: Challenge and Inspiration.

Bates SE.

Clin Cancer Res. 2017 Apr 1;23(7):1628. doi: 10.1158/1078-0432.CCR-16-2069. No abstract available.

28.

Too Many Journals.

Bates SE.

Oncologist. 2017 Feb;22(2):126-128. doi: 10.1634/theoncologist.2017-0012. Epub 2017 Feb 10. No abstract available.

29.

Multiple Myeloma: Multiplying Therapies.

Bates SE.

Clin Cancer Res. 2016 Nov 15;22(22):5418. doi: 10.1158/1078-0432.CCR-16-0624. No abstract available.

30.

DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes.

Jaramillo R, Shuck SC, Chan YS, Liu X, Bates SE, Lim PP, Tamae D, Lacoste S, O'Connor TR, Termini J.

Chem Res Toxicol. 2017 Feb 20;30(2):689-698. doi: 10.1021/acs.chemrestox.6b00414. Epub 2017 Feb 3.

31.

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, Fojo T.

Lancet Oncol. 2017 Jan;18(1):143-154. doi: 10.1016/S1470-2045(16)30633-7. Epub 2016 Dec 13.

PMID:
27979599
32.

Resuscitation of the Newborn: Simulating for Confidence.

Peacock PJ, Woodman A, McCay W, Bates SE.

Cureus. 2016 Sep 20;8(9):e790.

33.

Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.

Payabyab EC, Balasubramaniam S, Edgerly M, Velarde M, Merino MJ, Venkatesan AM, Leuva H, Litman T, Bates SE, Fojo T.

Clin Cancer Res. 2016 Oct 15;22(20):4989-5000.

34.

Endocrine Cancers: Defying the Paradigms.

Bates SE.

Clin Cancer Res. 2016 Oct 15;22(20):4980. No abstract available.

35.

Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.

Bahr JC, Robey RW, Luchenko V, Basseville A, Chakraborty AR, Kozlowski H, Pauly GT, Patel P, Schneider JP, Gottesman MM, Bates SE.

Oncotarget. 2016 Oct 25;7(43):69804-69815. doi: 10.18632/oncotarget.12001.

36.

ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.

O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, Bates SE.

Breast Cancer Res Treat. 2016 Nov;160(1):51-59. Epub 2016 Sep 12.

37.

Phase I Testing: 60 Years in the Making.

Bates SE.

Clin Cancer Res. 2016 Jun 1;22(11):2612. doi: 10.1158/1078-0432.CCR-15-2642. No abstract available.

38.

Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer.

O'Sullivan CC, Bates SE.

Oncologist. 2016 May;21(5):523-6. doi: 10.1634/theoncologist.2016-0108. Epub 2016 Apr 22. No abstract available.

39.

Disruptive Immunology.

Bates SE.

Clin Cancer Res. 2016 Apr 15;22(8):1844. doi: 10.1158/1078-0432.CCR-15-1850. No abstract available.

40.

Romidepsin Therapy Over 5 Years in a Clinical Setting-Real-world Experience.

Bates SE, Geskin LJ.

JAMA Oncol. 2016 Jun 1;2(6):794-5. doi: 10.1001/jamaoncol.2016.0072. No abstract available.

PMID:
27054784
41.

Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.

Bates SE, Fojo T.

Nat Rev Clin Oncol. 2016 Apr;13(4):205-6. doi: 10.1038/nrclinonc.2016.22. Epub 2016 Feb 23. No abstract available.

PMID:
26902963
42.

Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.

Massey PR, Wang R, Prasad V, Bates SE, Fojo T.

Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.

43.

The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.

Macalou S, Robey RW, Jabor Gozzi G, Shukla S, Grosjean I, Hegedus T, Ambudkar SV, Bates SE, Di Pietro A.

Cell Mol Life Sci. 2016 May;73(9):1927-37. doi: 10.1007/s00018-015-2118-5. Epub 2015 Dec 26.

PMID:
26708291
44.

UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.

Peer CJ, Goey AK, Sissung TM, Erlich S, Lee MJ, Tomita Y, Trepel JB, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

J Clin Pharmacol. 2016 Apr;56(4):450-60. doi: 10.1002/jcph.627. Epub 2015 Dec 4.

45.

How Do Cancer Cells Die?

Bates SE.

Clin Cancer Res. 2015 Nov 15;21(22):5014. doi: 10.1158/1078-0432.CCR-15-1203. No abstract available.

46.

Advancing Clinical Trials to Streamline Drug Development.

Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH.

Clin Cancer Res. 2015 Oct 15;21(20):4527-35. doi: 10.1158/1078-0432.CCR-15-0039.

47.

On Innovating and Inspiring the Clinical Trial Enterprise.

Bates SE.

Clin Cancer Res. 2015 Oct 15;21(20):4526. doi: 10.1158/1078-0432.CCR-15-0038. No abstract available.

48.

Assessing Adolescent Substance Abuse Programs with Updated Quality Indicators: The Development of a Consumer Guide for Adolescent Treatment.

Cacciola JS, Meyers K, Bates SE, Rosenwasser B, Arria A, McLellan AT.

J Child Adolesc Subst Abuse. 2015;24(3):142-154. Epub 2015 Mar 6.

49.

Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis.

Fatima N, Cohen DC, Sukumar G, Sissung TM, Schooley JF Jr, Haigney MC, Claycomb WC, Cox RT, Dalgard CL, Bates SE, Flagg TP.

Front Pharmacol. 2015 Aug 13;6:168. doi: 10.3389/fphar.2015.00168. eCollection 2015.

50.

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.

Goey AK, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, Ehrlich S, Bryla C, Balasubramaniam S, Piekarz R, Steinberg SM, Bates SE, Figg WD.

J Clin Pharmacol. 2016 Apr;56(4):461-73. doi: 10.1002/jcph.625. Epub 2015 Nov 9.

Supplemental Content

Loading ...
Support Center